secwatch.observer — SEC 8-K summary
======================================

Issuer:     Onconetix, Inc. (ONCO)
CIK:        0001782107
Form:       8-K
Filed at:   2023-06-14T23:59:59+00:00
Accession:  0001213900-23-048740
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Blue Water Biotech acquires six FDA-approved drugs for $8.5M cash and 1M shares
-------------------------------------------------------------------------------

- Total consideration $8.5M cash (payable in three tranches) plus 1.0M restricted shares of BWV common stock.
- Assets include ZONTIVITY (PAD/MI), OTOVEL/CETRAXAL (otic), CONJUPRI (hypertension), TREZIX/NALFON (pain).
- Closing subject to delivery of audited 2022 financials of seller’s parent and other customary conditions.
- Company will manage assets during pre-closing period; Blue Water becomes commercial-stage biopharma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782107/000121390023048740/0001213900-23-048740-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782107/000121390023048740/ea180344-8k_bluewater.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-048740

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer